JP6720225B2 - ヘテロアリール置換のアミノピリジン化合物 - Google Patents

ヘテロアリール置換のアミノピリジン化合物 Download PDF

Info

Publication number
JP6720225B2
JP6720225B2 JP2017566812A JP2017566812A JP6720225B2 JP 6720225 B2 JP6720225 B2 JP 6720225B2 JP 2017566812 A JP2017566812 A JP 2017566812A JP 2017566812 A JP2017566812 A JP 2017566812A JP 6720225 B2 JP6720225 B2 JP 6720225B2
Authority
JP
Japan
Prior art keywords
pyridin
carbonitrile
compound
alkyl
isopropylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017566812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524331A (ja
JP2018524331A5 (https=
Inventor
ジョン・ブイ・ダンシア
ダニエル・エス・ガードナー
ジョン・ハインズ
ジョン・イー・マコー
ジョゼフ・ビー・サンテラ
ウー・ホン
サティーシュ・ケサバン・ナイル
ベンカトラム・レディ・パイディ
カンダサミー・サルクナム
ラメシュ・クマール・シストラ
スッバ・ラオ・ポリメラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018524331A publication Critical patent/JP2018524331A/ja
Publication of JP2018524331A5 publication Critical patent/JP2018524331A5/ja
Application granted granted Critical
Publication of JP6720225B2 publication Critical patent/JP6720225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017566812A 2015-06-24 2016-06-23 ヘテロアリール置換のアミノピリジン化合物 Active JP6720225B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1880DE2015 2015-06-24
IN1880/DEL/2015 2015-06-24
PCT/US2016/038862 WO2016210037A1 (en) 2015-06-24 2016-06-23 Heteroaryl substituted aminopyridine compounds

Publications (3)

Publication Number Publication Date
JP2018524331A JP2018524331A (ja) 2018-08-30
JP2018524331A5 JP2018524331A5 (https=) 2019-07-18
JP6720225B2 true JP6720225B2 (ja) 2020-07-08

Family

ID=56345252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566812A Active JP6720225B2 (ja) 2015-06-24 2016-06-23 ヘテロアリール置換のアミノピリジン化合物

Country Status (9)

Country Link
US (1) US10202390B2 (https=)
EP (1) EP3313844B1 (https=)
JP (1) JP6720225B2 (https=)
CN (1) CN108026099B (https=)
AR (1) AR105114A1 (https=)
ES (1) ES2822956T3 (https=)
TW (1) TW201713663A (https=)
UY (1) UY36747A (https=)
WO (1) WO2016210037A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210036A1 (en) * 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
PE20191817A1 (es) 2017-05-11 2019-12-27 Bristol Myers Squibb Co Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
TWI727392B (zh) 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
CN112566697B (zh) 2018-08-13 2024-04-16 吉利德科学公司 作为IRAK4抑制剂的吡咯并[1,2-b]哒嗪衍生物
WO2020036830A1 (en) 2018-08-13 2020-02-20 Gilead Sciences, Inc. Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
CN114127075B (zh) * 2019-07-18 2024-05-14 百时美施贵宝公司 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物
EP3999508B1 (en) 2019-07-18 2023-08-30 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
JP7573596B2 (ja) * 2019-07-23 2024-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
WO2021026181A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
ES3059914T3 (en) 2019-08-13 2026-03-24 Bristol Myers Squibb Co Bicyclic heteroaryl compounds useful as irak4 inhibitors
EP4100408B1 (en) 2020-02-03 2024-02-28 Bristol-Myers Squibb Company Tricyclic heteroaryl compounds useful as irak4 inhibitors
WO2021158495A1 (en) 2020-02-03 2021-08-12 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors
EP4107158A1 (en) * 2020-02-19 2022-12-28 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
CN113149995A (zh) * 2021-03-31 2021-07-23 安徽驱石医药科技有限公司 一种7-氟吡唑并[1,2-b]吡嗪-4-甲腈的合成方法及应用
FI4367118T3 (fi) 2021-08-18 2025-04-09 Nurix Therapeutics Inc Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825190B2 (en) 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CA2531401A1 (en) 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2663091A1 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
KR20100020454A (ko) 2007-06-08 2010-02-22 바이엘 크롭사이언스 소시에떼아노님 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
JPWO2010058846A1 (ja) 2008-11-21 2012-04-19 アステラス製薬株式会社 ４，６−ジアミノニコチンアミド化合物
WO2010061971A1 (ja) 2008-11-28 2010-06-03 興和株式会社 ピリジン－３－カルボキシアミド誘導体
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2493863B1 (en) 2009-10-30 2015-02-25 Janssen Pharmaceutica NV Phenoxy-substituted pyrimidines as opioid receptor modulators
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
CN103619854A (zh) 2011-04-29 2014-03-05 西奈山伊坎医学院 激酶抑制剂
WO2013106614A1 (en) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104254533B (zh) * 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
KR20150079963A (ko) * 2012-11-08 2015-07-08 브리스톨-마이어스 스큅 컴퍼니 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
CN104781251B (zh) 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
TW201609693A (zh) * 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
ES2822956T3 (es) 2015-06-24 2021-05-05 Bristol Myers Squibb Co Compuestos de aminopiridina sustituidos con heteroarilo

Also Published As

Publication number Publication date
WO2016210037A1 (en) 2016-12-29
US20180179213A1 (en) 2018-06-28
ES2822956T3 (es) 2021-05-05
JP2018524331A (ja) 2018-08-30
CN108026099A (zh) 2018-05-11
AR105114A1 (es) 2017-09-06
UY36747A (es) 2016-12-30
US10202390B2 (en) 2019-02-12
EP3313844A1 (en) 2018-05-02
EP3313844B1 (en) 2020-08-26
CN108026099B (zh) 2020-07-10
TW201713663A (zh) 2017-04-16

Similar Documents

Publication Publication Date Title
JP6720225B2 (ja) ヘテロアリール置換のアミノピリジン化合物
JP7154229B2 (ja) Ｉｒａｋ－４阻害剤として有用なチエノピリジンおよびベンゾチオフェン
US10294229B2 (en) Heteroaryl substituted aminopyridine compounds
JP6720355B2 (ja) ヘテロアリール置換のアミノピリジン化合物
KR102930924B1 (ko) Irak4 억제제로서 유용한 비시클릭 헤테로아릴 화합물
JP2022532145A (ja) 置換ベンズイミダゾロン化合物
US12304914B2 (en) Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as IRAK4 inhibitors
US12304916B2 (en) Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors
CA2487948A1 (en) Azole methylidene cyanide derivatives and their use as protein kinase modulators
JP2022543143A (ja) Ｉｒａｋ４阻害剤として有用な二環ヘテロ環式化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200617

R150 Certificate of patent or registration of utility model

Ref document number: 6720225

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250